Cargando…

Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility

The treatment modality of gastric adenocarcinoma (GCA) depends on the stage of the disease at the clinical presentation. Long delays are probably an unfavorable factor for the patient's prognosis. A prospective longitudinal, study involving 145 consecutive GCA was conducted at the National Hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Subasinghe, D., Mahesh, P. K. B., Wijesinghe, G. K., Sivaganesh, S., Samarasekera, A., Lokuhetty, M. D. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667260/
https://www.ncbi.nlm.nih.gov/pubmed/37996431
http://dx.doi.org/10.1038/s41598-023-47415-y
_version_ 1785149028094181376
author Subasinghe, D.
Mahesh, P. K. B.
Wijesinghe, G. K.
Sivaganesh, S.
Samarasekera, A.
Lokuhetty, M. D. S.
author_facet Subasinghe, D.
Mahesh, P. K. B.
Wijesinghe, G. K.
Sivaganesh, S.
Samarasekera, A.
Lokuhetty, M. D. S.
author_sort Subasinghe, D.
collection PubMed
description The treatment modality of gastric adenocarcinoma (GCA) depends on the stage of the disease at the clinical presentation. Long delays are probably an unfavorable factor for the patient's prognosis. A prospective longitudinal, study involving 145 consecutive GCA was conducted at the National Hospital of Sri Lanka (NHSL). The overall delay (in weeks) was recorded for each patient and divided into four periods-patient, endoscopy, pathology and treatment. The median and Interquartile Range (IQR) duration of delays were calculated and differences were explored with chi square test and Mann Whitney U test Survival analysis was done with Kaplan Meier technique and Cox regression. The median duration of delays for patient, endoscopy, histology reporting delay, other histology delay (specimen transfer delay and report receipt delay) and treatment were 18 (IQR 14–27), 2 (IQR 2–3), 3 (IQR 2–3), 2 (IQR 1–2) and 6 (IQR 4–8) weeks respectively. Delayed patient presentation to hospital was associated with significant adverse median survival 16 (IQR 11.5–22.5) weeks versus 20 (IQR 16–27.5) weeks, p = 0.004. Delay in initiating treatment was associated with significantly lower median survival 04 (IQR 4–6) weeks versus 06 (IQR 4–8) weeks, p = 0.003. Over 60% of both proximal and distal GCA presented at an advanced radiological stage (stage III/IV). The Kaplan Meier analysis showed that the higher hazard function was associated with a higher tumour stage and undergoing chemotherapy. Age of the patient and the treatment modality were significant predictors of the survival. Patient delay and delay in initiation of definitive treatment are the most important factors that adversely affect the outcomes of GCA. Public health interventions aiming to shorten the patient delay time with proper referral for specialist care would play an important role. Also, it is important to minimize these preventable delays and there should be time limits in producing the histopathology report and to establish online portals of hospital and laboratory information systems for easy access of histology reports in future.
format Online
Article
Text
id pubmed-10667260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106672602023-11-23 Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility Subasinghe, D. Mahesh, P. K. B. Wijesinghe, G. K. Sivaganesh, S. Samarasekera, A. Lokuhetty, M. D. S. Sci Rep Article The treatment modality of gastric adenocarcinoma (GCA) depends on the stage of the disease at the clinical presentation. Long delays are probably an unfavorable factor for the patient's prognosis. A prospective longitudinal, study involving 145 consecutive GCA was conducted at the National Hospital of Sri Lanka (NHSL). The overall delay (in weeks) was recorded for each patient and divided into four periods-patient, endoscopy, pathology and treatment. The median and Interquartile Range (IQR) duration of delays were calculated and differences were explored with chi square test and Mann Whitney U test Survival analysis was done with Kaplan Meier technique and Cox regression. The median duration of delays for patient, endoscopy, histology reporting delay, other histology delay (specimen transfer delay and report receipt delay) and treatment were 18 (IQR 14–27), 2 (IQR 2–3), 3 (IQR 2–3), 2 (IQR 1–2) and 6 (IQR 4–8) weeks respectively. Delayed patient presentation to hospital was associated with significant adverse median survival 16 (IQR 11.5–22.5) weeks versus 20 (IQR 16–27.5) weeks, p = 0.004. Delay in initiating treatment was associated with significantly lower median survival 04 (IQR 4–6) weeks versus 06 (IQR 4–8) weeks, p = 0.003. Over 60% of both proximal and distal GCA presented at an advanced radiological stage (stage III/IV). The Kaplan Meier analysis showed that the higher hazard function was associated with a higher tumour stage and undergoing chemotherapy. Age of the patient and the treatment modality were significant predictors of the survival. Patient delay and delay in initiation of definitive treatment are the most important factors that adversely affect the outcomes of GCA. Public health interventions aiming to shorten the patient delay time with proper referral for specialist care would play an important role. Also, it is important to minimize these preventable delays and there should be time limits in producing the histopathology report and to establish online portals of hospital and laboratory information systems for easy access of histology reports in future. Nature Publishing Group UK 2023-11-23 /pmc/articles/PMC10667260/ /pubmed/37996431 http://dx.doi.org/10.1038/s41598-023-47415-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Subasinghe, D.
Mahesh, P. K. B.
Wijesinghe, G. K.
Sivaganesh, S.
Samarasekera, A.
Lokuhetty, M. D. S.
Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
title Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
title_full Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
title_fullStr Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
title_full_unstemmed Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
title_short Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
title_sort delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667260/
https://www.ncbi.nlm.nih.gov/pubmed/37996431
http://dx.doi.org/10.1038/s41598-023-47415-y
work_keys_str_mv AT subasinghed delayindiagnosistotreatmentandimpactonsurvivalofgastricadenocarcinomainalowincomesettingwithoutscreeningfacility
AT maheshpkb delayindiagnosistotreatmentandimpactonsurvivalofgastricadenocarcinomainalowincomesettingwithoutscreeningfacility
AT wijesinghegk delayindiagnosistotreatmentandimpactonsurvivalofgastricadenocarcinomainalowincomesettingwithoutscreeningfacility
AT sivaganeshs delayindiagnosistotreatmentandimpactonsurvivalofgastricadenocarcinomainalowincomesettingwithoutscreeningfacility
AT samarasekeraa delayindiagnosistotreatmentandimpactonsurvivalofgastricadenocarcinomainalowincomesettingwithoutscreeningfacility
AT lokuhettymds delayindiagnosistotreatmentandimpactonsurvivalofgastricadenocarcinomainalowincomesettingwithoutscreeningfacility